Supplementary Table S1. Dose levels of ASTX660 by cohort

Cohort #	Dose, mg/d[a]	DLT	Evaluable patients, n	Note
1	15 (PiB)	N/A	3	
2	30 (PiB)	No	3	
3	60 (PiB)	No	4	
4	120 (PiB)	No	3	
5	180 (PiB)	No	3	Decision to transition to Cap formulation at same dose (180 mg/d)
6	180 (Cap)	No	3	
7	270 (Cap)	Yes (n=2)	6	2 DLTs (grade 3 increased lipase and grade 3 hyperlipasemia), which prompted decision to de-escalate to 210 mg/d
8	210 (Cap)	Yes (n=1)	8	1 DLT (grade 3 increased lipase); DSRC reviewed available safety, PK, and PD data, and reached consensus to expand 180-mg/d Cap dose level up to 12 patients in part 2 (dose expansion)
Part 2	180 (Cap)	No	—	DSRC reviewed available data from dose escalation and expansion, and determined 210 mg/d the MTD and 180 mg/d the RP2D

[a]Dosing schedule for all cohorts occurred as follows: 7 days on/7 days off x 2 (28-day cycle).
Cap, capsule; DSRC, data and safety review committee.